ACTA OPHTHALMOLOGICA 审稿速度-刊鹿论文编译

The value of cycloplegia in optometric refraction of adults in a population study

Abstract:

nosis of cytomegalovirus retinitis (CMVR) after HSCT is mainly based on clinical history and ophthalmic examination (Port et al. 2017). The traditional treating end-point is also depended on clinical findings, usually described as ‘complete quiescence’ of lesion on the retina in literature (Choopong et al. 2016). But in clinical practice, signs acquired by fundus examination are not always in accordance with actual state of the disease. Here, we conducted an assessment of an antiviral strategy for CMVR after HSCT, using aqueous CMV-DNA load and interleukin-8 (IL-8) level as quantitative variables. Prospective consecutive series of nine patients (15 eyes) who diagnosed as CMVR base on clinical history and fundus examination were given systemic and intravitreous injection of antiviral drugs. Intravitreous injection of ganciclovir (IVG) 3 mg was given to every patient, twice per week for four times (induction phase). Aqueous and serum sample was collected 1 day before the first injection (baseline), during the fourth time of injection, and then every time since the fifth injection. Serum CMV-DNA load, aqueous CMV-DNA load and aqueous IL-8 level were determined by real-time PCR and cytometric beads array, respectively. Compared with baseline, if aqueous CMV-DNA load decreased by two magnitudes or IL-8 level decreased by one magnitude acquired during the fourth injection, IVG 3 mg would continue to be given weekly (maintenance phase), otherwise, therapy would be adjusted to IVG 3 mg combined with foscarnet sodium 2.4 mg once per week (maintenance phase). Local treating end-point was defined as negative aqueous CMVDNA load (<1.0 9 10 copies/ml) or IL-8 level (<30 pg/ml). Then patients were requested to come back every other week and followed up for 3 months at least. Systemic treating end-point was defined as negative serum CMV-DNA after local treating end-point had been reached. Best corrected visual acuity (BCVA, in form of Logarithm of the minimum angle of resolution, LogMAR), intraocular pressure (IOP; Goldmann applanation tonometry), ophthalmic examination using slit-lamp microscope were performed during each time of visit. Patients were evaluated and followed up for a median of 5 months (3– 7 months). Best corrected visual acuity (BCVA) and IOP at base line and last time of visit were (0.679 0.552; LogMAR) and (0.641 0.609; LogMAR), (17.2 5.9) mmHg and (15.9 5.9) mmHg, respectively. No significant difference was found between baseline and last time of visit (p = 0.554 and p = 0.864, respectively). The median times of intravitreous injection were six times (4–11 times). At local treating endpoint, systemic antiviral drugs were stopped for all patients, but vessel infiltration, exudation and haemorrhage still could be found in 13 of 15 eyes during fundus examination. Negative aqueous CMV-DNA was found in six eyes (40%), but CMV-DNA could still be detected in nine eyes (60%), while aqueous IL-8 was negative. Median follow-up period was 5 months (3–7 months). At last time of visit, all CMVR lesions became quiescent completely, without any signs of recurrence. Our data indicated that, none of the nine patients experienced recurrence at the last visit, even if CMV-DNA still could be detected in nine eyes at local treating end-point. Furthermore, lesion on the retina continued healing until complete quiescent was achieved even after both systemic and local antiviral therapies were stopped, which proved the efficacy and safety of this strategy. If local treating end-point was set as ‘negative aqueous CMV-DNA’ or ‘complete quiescent lesions on retina’, which is described in literature, the treatment duration must be much longer than actual needs. In summary, aqueous CMV-DNA and IL-8 are excellent quantitative variables that could be used to adjust local antiviral treatment and provide local treating end-point effectively, safely and efficiently.

Author Listing： Catherine Jan;Nathan Congdon;Weihe Zhou;Brendan Ross;Ningli Wang;Yuanbo Liang

Volume： 97

Pages： None

DOI： 10.1111/aos.13933

Language： English

Journal： Acta Ophthalmologica

ACTA OPHTHALMOLOGICA

ACTA OPHTHALMOL

影响因子：3.0

是否综述期刊：否

是否OA：否

是否预警：不在预警名单内

发行时间：-

ISSN：1755-375X

发刊频率：Bimonthly

收录数据库：SCIE/Scopus收录

出版国家/地区：DENMARK

出版社：Wiley-Blackwell Publishing Ltd

期刊介绍

Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER).Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.

《眼科学报》代表《斯堪的纳维亚眼科学报》基金会出版，是以下学会的官方科学出版物：丹麦眼科学会、芬兰眼科学会、冰岛眼科学会、挪威眼科学会和瑞典眼科学会，以及欧洲视觉和眼科研究协会（EVER）.Acta Ophthalmologica发表临床和实验原创文章、评论、社论、教育摄影论文（眼科诊断和治疗）、病例报告和病例系列、致编辑的信件和博士论文。

年发文量	171
国人发稿量	13
国人发文占比	7.6%
自引率	6.7%
平均录取率	约75%
平均审稿周期	平均6月
版面费	US$4700
偏重研究方向	医学-眼科学
期刊官网	http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-3768
投稿链接	https://mc.manuscriptcentral.com/acta

质量指标占比

研究类文章占比	OA被引用占比	撤稿占比	出版后修正文章占比
83.63%	42.33%	0.00%	0.60%

预警情况查看说明

时间	预警情况
2024年02月发布的2024版	不在预警名单中
2023年01月发布的2023版	不在预警名单中
2021年12月发布的2021版	不在预警名单中
2020年12月发布的2020版	不在预警名单中

JCR分区 WOS分区等级：Q1区

版本	按学科	分区
WOS期刊SCI分区 WOS期刊SCI分区是指SCI官方（Web of Science）为每个学科内的期刊按照IF数值排序，将期刊按照四等分的方法划分的Q1-Q4等级，Q1代表质量最高，即常说的1区期刊。（2021-2022年最新版）
	OPHTHALMOLOGY	Q1

关于2019年中科院分区升级版（试行）

分区表升级版（试行）旨在解决期刊学科体系划分与学科发展以及融合趋势的不相容问题。由于学科交叉在当代科研活动的趋势愈发显著，学科体系构建容易引发争议。为了打破学科体系给期刊评价带来的桎梏，“升级版方案”首先构建了论文层级的主题体系，然后分别计算每篇论文在所属主题的影响力，最后汇总各期刊每篇论文分值，得到“期刊超越指数”，作为分区依据。

分区表升级版（试行）的优势：一是论文层级的主题体系既能体现学科交叉特点，又可以精准揭示期刊载文的多学科性；二是采用“期刊超越指数”替代影响因子指标，解决了影响因子数学性质缺陷对评价结果的干扰。整体而言，分区表升级版（试行）突破了期刊评价中学科体系构建、评价指标选择等瓶颈问题，能够更为全面地揭示学术期刊的影响力，为科研评价“去四唯”提供解决思路。相关研究成果经过国际同行的认可，已经发表在科学计量学领域国际重要期刊。

《2019年中国科学院文献情报中心期刊分区表升级版（试行）》首次将社会科学引文数据库（SSCI）期刊纳入到分区评估中。升级版分区表（试行）设置了包括自然科学和社会科学在内的18个大类学科。基础版和升级版（试行）将过渡共存三年时间，推测在此期间各大高校和科研院所仍可能会以基础版为考核参考标准。提示：中科院分区官方微信公众号“fenqubiao”仅提供基础版数据查询，暂无升级版数据，请注意区分。

中科院分区查看说明

版本	大类学科	小类学科	Top期刊	综述期刊
	医学 3区	OPHTHALMOLOGY 眼科学 3区	否	否
2021年12月基础版	医学 3区	OPHTHALMOLOGY 眼科学 2区	否	否
2021年12月升级版	医学 3区	OPHTHALMOLOGY 眼科学 2区	否	否
2020年12月旧的升级版	医学 2区	OPHTHALMOLOGY 眼科学 2区	否	否
2022年12月最新升级版	医学 3区	OPHTHALMOLOGY 眼科学 2区	否	否